Viamet spinout Innocrin Pharma raises $8M for hard-to-treat prostate cancer
Innocrin Pharmaceuticals, the spanking-new spinout of successful antifungal company Viamet, just raised $8 million according to regulatory filings. The company has taken Viamet’s findings and translated them as a therapy for a tough-to-treat form of prostate cancer. This past October, Viamet withdrew its plans to go public in favor of raising $60 million in private equity […]